<DOC>
	<DOCNO>NCT02314182</DOCNO>
	<brief_summary>A prospective , open , multicenter , randomize III trial two arm : - Arm A : Primary tumor resection , follow chemotherapy - Arm B : Chemotherapy alone . Compare overall 2-year survival rate patient treat resectable rectal adenocarcinoma unresectable metastasis , treat either primary tumor resection chemotherapy +/- target therapy , chemotherapy ( +/- target therapy ) alone .</brief_summary>
	<brief_title>GRECCAR 8 : Primary Tumor Resection Rectal Cancer With Unresectable Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Noncomplicated primary tumor ( i.e . tumor without obstruction , bleeding , abscess perforation require emergency surgery and/or contraindicate firstline chemotherapy ) Unresectable synchronous metastasis ECOG performance status 01 Rectal adenocarcinoma ( &lt; 15 cm anal verge ) symptoms unresectable metastasis ( assessed investigator ) unsuitable curative treatment No known unresectable primary tumor ( clear margin &gt; 1mm ) CTscan MRI No disease progression chemotherapy ( least 4 cycle ) ; Assessment KRAS status randomization ( wild type mutate ) ; Life expectancy without cancer &gt; 2 year White blood cell count ≥ 3 x 109/L , neutrophil ≥ 1,5 x 109/L , platelet count ≥ 100 x 109/L , hemoglobin°≥ 9 g/dL ( 5,6 mmol/l ) Total bilirubin ≤ 1.5 x ULN ( upper limit normal ) , ASAT ALAT ≤ 2.5 x ULN , alkaline phosphatase°≤°1.5°x ULN , serum creatinine ≤ 1.5 x ULN ; Age ≥ 18 year ≤ 75 year Patients childbearing potential use effective contraception study 6 month end chemotherapy Covered Health System applicable , and/or compliance recommendation national law force relate biomedical research ; Signed write informed consent obtain prior studyspecific screening procedure Rectal tumor operate inclusion Symptoms relate rectal tumor require first intention rectal surgery ( appreciated investigator ) Contraindication surgery Resectable metastasis Complicated ( obstruction , bleeding , abscess , perforation ) primary tumor require emergency surgery and/or contraindicate first linechemotherapy Nonresectable primary tumor ( wild margin ) Age &gt; 75 year &lt; 18 year ECOG performance status &gt; 2 Under nutrition ( albumin &lt; 30 g/l ) Peritoneal carcinomatosis Disease progression chemotherapy ( RECIST 1.1 criterion ) Known hypersensitivity reaction specific contraindication component study treatment Clinically relevant coronary artery disease history myocardial infarction last 12 month , high risk uncontrolled arrhythmia Pregnancy ( absence confirm ßhCG test ) breastfeeding ; Previous malignancy last 5 year Medical , geographical , sociological , psychological legal condition would prevent patient complete study signing informed consent ; investigator 's opinion Any significant disease , investigator 's opinion , excludes patient study Under administrative legal supervision .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Rectal adenocarcinoma</keyword>
	<keyword>unresectable</keyword>
	<keyword>surgery</keyword>
	<keyword>chemotherapy</keyword>
</DOC>